Brooke M. Rock, PhD

Director, Department of Pharmacokinetics & Drug Metabolism @ Amgen Inc.

GalNAc Targeted Liver Delivery of siRNAs and Small Molecules/Bispecific Ab's

Roger D. Kamm, PhD

Cecil and Ida Green Distinguished Professor of Biological and Mechanical Engineering @ MIT

Vascular and Lymphatic Barrier Function in the Brain and Subcutaneous Compartments

Mailys De Sousa Mendes, PhD

Senior Research Scientist @ Certara UK

Mechanistic Modeling of Caco-2 Experiments to Estimate Intrinsic Permeability

Li Di, PhD

Research Fellow @ Pfizer, Inc.

Prediction Accuracy of Volume of Distribution Using In Vitro, In Vivo, PBPK and QSAR Methods

Charles Knutson, PhD

Associate Director @ Novartis Institutes for BioMedical Research

Panel Discussion

James Kozloski, PhD

Principal Research Scientist @ IBM

Populations of Models for Virtual Patient/Cohort Construction in ADME/PK

Ryan Pelis, PhD

Senior Investigator I @ Novartis Institutes for BioMedical Research

Tools Toward Predicting Oral Lymphatic Absorption

Haojing Rong, PhD

Vice President of Preclinical Development @ Kymera Therapeutics

The Knowns and Unknowns of ADME/PK of Targeted Protein Degraders

Yuanxin Xu, PhD

Sr. VP of Early Development and Translational Medicine @ Intellia Therapeutics, Inc.

Of Mice and Man: Path to Clinical CRISPR/Cas9 Genome Editing Therapeutic Development

Doug Burdette, PhD

Director of DMPK and Clinical Pharmacology @ Moderna Therapeutics, Inc.

Title TBA

Dipen Vyas, PhD

Study Director (ADME-Tox) @ BioIVT

Long-term HEPATOPAC® Cultures: Model Validation for ADME-Tox Applications

Panel Discussion:

Expedited Drug Discovery Post-COVID 

 Participants:

Brooke Rock, Amgen

Doug Burdette & Lei Ci, Moderna

Charlie Knutson, Novartis